For laboratory research use only (in vitro). Not for human or animal use.
| Quantity | Discount | Unit Price |
|---|---|---|
| 1-2 units | Standard | $103.99 |
| 3-4 units | 5% off | $98.79 |
| 5-9 units | 10% off | $93.59 |
| 10+ units Best Value | 15% off | $88.39 |
Why researchers choose PBC:
Accepted payment methods:
Certificate of Analysis available upon request. Contact us for lot-specific documentation.
| Amino Acid Sequence | Modified 37-amino acid amylin analog with strategic substitutions and C18 fatty diacid acylation via glutamic acid-based linker |
|---|---|
| Molecular Weight | 4030 Da |
| Molecular Formula | C194H312N54O59S2 |
| CAS Number | 2170438-03-2 |
| Purity | ≥98% (HPLC) |
| Format | Lyophilized Powder |
| Vials Per Kit | 10 |
| Storage | Store at -20C. Reconstituted: 2-8C |
| Research Status | Phase3 |
For laboratory research use only (in vitro). Not for human or animal use.
Cagrilintide analytical reference compound. Molecular weight 4030 Da.
| Sequence | Modified 37-amino acid amylin analog with strategic substitutions and C18 fatty diacid acylation via glutamic acid-based linker |
| Molecular Weight | 4030 Da |
| Molecular Formula | C194H312N54O59S2 |
| CAS | 2170438-03-2 |
| Purity | >=98% (HPLC) |
| Format | Lyophilized powder |
| Storage | Store at -20C. Reconstituted: 2-8C |
For laboratory research use only (in vitro). Not for human or animal use.
| Size | 5mg, 10mg |
|---|
4 references
References are provided for informational purposes to support in vitro laboratory research. No claims are made regarding therapeutic applications.
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietilainen KH, Rubino D, Batterham RL (2021). The Lancet. PubMed 34798060
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial
Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW (2021). The Lancet. PubMed 33894838
Efficacy and safety of cagrilintide plus semaglutide in type 2 diabetes: a multicentre, randomised, double-blind, phase 2 trial
Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Machineni S, Mathieu C, Philis-Tsimikas A, Rosenstock J (2023). The Lancet. PubMed 37364590
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
D'Ascanio AM, Mullally JA, Frishman WH (2024). Cardiology in Review. PubMed 36883831
For laboratory research use only (in vitro). Not for human or animal use.